Literature DB >> 26481593

TROP-2 expression in papillary thyroid carcinoma: Potential Diagnostic Utility.

Anthony Simms1, Reuben P Jacob1, Cynthia Cohen1, Momin T Siddiqui1.   

Abstract

TROP-2 is a type I transmembrane glycoprotein which is over-expressed in various malignancies, and is related to epithelial cell adhesion molecule (EpCAM), also called TROP-1, gp40, and KSA. In this study, we evaluated TROP-2 expression in papillary thyroid carcinoma (PTC) and compared it to other thyroid neoplastic and non-neoplastic lesions. Immunohistochemical (IHC) evaluation for TROP-2 was performed on 137 thyroid fine needle aspiration (FNA) cell blocks (CB) which included classic PTC (64), follicular variant PTC (FVPTC) (10), anaplastic thyroid carcinoma (AC) (2), medullary carcinoma (MC) (8), follicular neoplasms (FN) (8), Hurthle cell neoplasms (HCN) (9), follicular lesion of uncertain significance (FLUS) (12), and benign thyroid nodule (BTN) (24). IHC for TROP-2 expression was also performed on 331 BTN and malignant tumor tissue sections in tissue microarray (TMA). Membranous staining in >5% of tumor cells was considered positive. TROP-2 stained 61 of 64 PTC CB, 7 of 10 FVPTC CB, and 9 of 12 FLUS CB. All other cases were negative for TROP-2. TROP-2 showed a sensitivity of 95.31% and specificity of 89% for classic PTC in FNA CB. In TMA samples, TROP-2 stained 54 of 60 classic PTC cases and hence showed a high sensitivity and specificity. All BTN in CB and TMA were negative. We conclude that TROP-2 is a highly sensitive and specific IHC marker for identifying classic PTC. TROP-2 may play an important role in diagnosing classic PTC, especially in equivocal cases. This study also identifies a strong role for TROP-2 in separating PTC from BTN.
© 2015 Wiley Periodicals, Inc.

Entities:  

Keywords:  TROP-2; fine needle aspiration; immunohistochemistry; papillary thyroid carcinoma

Mesh:

Substances:

Year:  2015        PMID: 26481593     DOI: 10.1002/dc.23382

Source DB:  PubMed          Journal:  Diagn Cytopathol        ISSN: 1097-0339            Impact factor:   1.582


  6 in total

1.  The diagnostic value of TROP-2, SLP-2 and CD56 expression in papillary thyroid carcinoma.

Authors:  Xueyang Yang; Yifang Hu; He Shi; Chengzhou Zhang; Zhixiao Wang; Xiaoyun Liu; Huanhuan Chen; Lijuan Zhang; Dai Cui
Journal:  Eur Arch Otorhinolaryngol       Date:  2018-06-27       Impact factor: 2.503

2.  The Significance of TROP2 Expression in Predicting BRAF Mutations in Papillary Thyroid Carcinoma.

Authors:  Joon Seog Kong; Hyeon Jin Kim; Min-Jung Kim; Areumnuri Kim; Dalnim Lee; Kanghee Han; Sunhoo Park; Jae Soo Koh; Jae Kyung Myung
Journal:  J Pathol Transl Med       Date:  2017-12-11

Review 3.  The emergence of trophoblast cell-surface antigen 2 (TROP-2) as a novel cancer target.

Authors:  David M Goldenberg; Rhona Stein; Robert M Sharkey
Journal:  Oncotarget       Date:  2018-06-22

Review 4.  Trop2: Jack of All Trades, Master of None.

Authors:  Sára Lenárt; Peter Lenárt; Jan Šmarda; Ján Remšík; Karel Souček; Petr Beneš
Journal:  Cancers (Basel)       Date:  2020-11-11       Impact factor: 6.639

5.  DNA repair pathway activation features in follicular and papillary thyroid tumors, interrogated using 95 experimental RNA sequencing profiles.

Authors:  Uliana Vladimirova; Pavel Rumiantsev; Marianna Zolotovskaia; Eugene Albert; Aleksander Abrosimov; Konstantin Slashchuk; Petr Nikiforovich; Olga Chukhacheva; Nurshat Gaifullin; Maria Suntsova; Galina Zakharova; Alexander Glusker; Daniil Nikitin; Andrew Garazha; Xinmin Li; Dmitriy Kamashev; Alexei Drobyshev; Irina Kochergina-Nikitskaya; Maxim Sorokin; Anton Buzdin
Journal:  Heliyon       Date:  2021-03-13

Review 6.  Trop-2 protein as a therapeutic target: A focused review on Trop-2-based antibody-drug conjugates and their predictive biomarkers.

Authors:  Semir Vranic; Zoran Gatalica
Journal:  Bosn J Basic Med Sci       Date:  2022-02-01       Impact factor: 3.363

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.